Corresponding to our results from subset 1, a trend towards shorter DFS in PRL-3-positive carcinomas compared to patients with PRL-3-negative carcinomas was also observed the series of patients with longer follow-up (subset 2) with a mean DFS of 118±11 months (95% CI, 97–139) in PRL-3-positive vs 138±18 months (95% CI, 103–172; P=0.330) in PRL-3-negative patients, respectively. This evidence concerns the gene PTP4A3 and carcinoma.